Core Insights - Biofrontera Inc. announced preliminary unaudited revenue results for Q4 2025, expecting revenues between $17.0 million and $17.5 million, marking the highest quarterly revenue in the company's history [1][8] - For the full year 2025, revenues are projected to be between $41.5 million and $42.0 million, indicating a year-over-year growth of approximately 11% to 13% [2][8] - The strong performance in Q4 was attributed to effective sales execution of Ameluz® PDT and a pricing adjustment made in December [3][8] Financial Performance - Q4 2025 revenues are expected to show a year-over-year growth of 35% to 39% driven by the sales of Ameluz® [8] - The company anticipates reporting complete financial results for Q4 and the full year 2025 in March 2026 [2][4] Strategic Developments - The recent transaction with Biofrontera AG is expected to significantly improve the company's gross margin profile and strengthen its financial foundation [4] - The CEO expressed confidence in the company's innovative products and operational excellence, which are expected to drive sustainable growth in 2026 [3][4] Upcoming Events - Biofrontera management is scheduled to present at the Lytham Partners Healthcare Investor Summit on January 15, 2026 [5]

Core Insights - Biofrontera Inc. has engaged Lytham Partners to enhance its investor relations and shareholder communication strategy, aiming to broaden its investor base and improve market recognition of its value proposition [1][3]. Company Overview - Biofrontera Inc. is a biopharmaceutical company focused on photodynamic therapy (PDT) for dermatological conditions, particularly through its drug-device combination Ameluz® and the RhodoLED® lamp series [4]. - The company is actively conducting clinical trials to expand the application of its products to treat non-melanoma skin cancers and moderate to severe acne [4]. Recent Developments - The company has undertaken significant actions, including restructuring its relationship with its former parent company, acquiring U.S. intellectual property, and securing $11 million in new funding, positioning itself for potential profitability in upcoming quarters [3]. - Biofrontera aims to establish itself as a leading specialty dermatology company in the U.S. by advancing innovative therapies that cater to dermatology professionals and their patients [3]. Strategic Partnership - Lytham Partners, with over 20 years of experience in investor relations, will provide a comprehensive platform for Biofrontera to enhance its visibility among institutional investors and streamline its communication practices [2]. - The partnership is expected to support Biofrontera in keeping shareholders informed about the company's developments and progress [3].